Drug Trial Radar · NCT00514475
Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: May 4, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Nov 2005
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- Oslo University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 10, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine if outcome for patients with mantle cell lymphoma is improved by adding radioimmunotherapy to high-dose regimen before auto-transplant in patients who are not in CR after induction therapy.
Conditions
- Mantle Cell Lymphoma
Interventions
90Y-ibritumomab tiuxetan (Zevalin)Drug
90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to treatment failure (TTF) for PR/CRu patients receiving Zevalin-BEAM/BEACTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Arne Kolstad
Oslo, Oslo, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.